読み込み中
NASDAQHealthcareMedical - Diagnostics & Research
最新データ
$3.37
+$0.09 · +2.74%
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
前日終値
$3.37
+$0.09 · +2.74%
日中の時刻はETです。市場データは遅延する場合があります。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日中レンジ
現在 $3.37
52週レンジ
現在 $3.37
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
38
割高
センチメント
44
まちまち
リスク
71
高リスク
モメンタム
31
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
日中レンジ
現在 $3.37
52週レンジ
現在 $3.37
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 405.5万 USD | 188.1万 USD | 150.3万 USD | 95.8万 USD | 219.8万 USD |
| 売上原価 | 386.5万 USD | 114.1万 USD | 109万 USD | 97.6万 USD | 77.8万 USD |
| 粗利益 | 19万 USD | 74万 USD | 41.3万 USD | −1.8万 USD | 142万 USD |
| 研究開発 | 1590万 USD | 983.9万 USD | 929.4万 USD | 730.1万 USD | 503.5万 USD |
| 販売・一般管理 | 1697.6万 USD | 1378.5万 USD | 1328.5万 USD | 2153.3万 USD | 2039.2万 USD |
| 営業費用 | 3076.8万 USD | 6178.1万 USD | 2554.9万 USD | 1797.9万 USD | 5514.5万 USD |
| 支払利息 | 10.9万 USD | 8.4万 USD | 5.2万 USD | 8.3万 USD | 20.9万 USD |
| 減価償却費と償却費 | 219.7万 USD | 156.4万 USD | 168万 USD | 522万 USD | 420.5万 USD |
| 営業利益 | −3057.8万 USD | −6104.1万 USD | −2513.6万 USD | −1799.7万 USD | −5372.5万 USD |
| 純利益 | −5022.2万 USD | −6066.3万 USD | −2778.1万 USD | −7290.2万 USD | −6409.7万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$9.75
上昇余地（189.32%）| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2023年7月25日 | 1:20 | — | — |
発効済み 2023年7月25日
1:20
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
